本帖最后由 老马 于 2012-1-13 21:20 编辑
; T' p' J6 T4 ]6 ^2 C( O
. b; u' \, C5 ^9 g& d5 ~爱必妥和阿瓦斯丁的比较
# K2 j3 w/ ]) m' v% ^
0 {% N" M; J4 x; bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/& G. }) \8 Z; |( m3 r
2 g+ s2 B3 _" x5 l
. m# ^5 ~. \$ Z; X) ~3 N; I' y. C& i
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
- k: J3 t* H" N x1 t==================================================; g6 O2 r7 o$ ]4 H7 a: l9 q: X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) V1 T. U$ j8 qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* B' A2 A* v# e1 {) W" v
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 ]3 g. P6 O# B( i0 U4 P
|